SHIONOGI Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) announced a profit for its first quarter that Increased, from the same period last yearThe company's bottom line came in at JPY97.696 billion, or JPY......

Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized....

QBTS expands into AI and blockchain via a live quantum-classical testNet with Postquant Labs and early drug discovery gains with Shionogi....

Shionogi & Co.'s experimental Covid-19 pill cut the risk of infection among people exposed to the disease at home, according to a study that could revive interest in antivirals as a preventive tool....

TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) revealed earnings for its full year that Increased, from last yearThe company's bottom line totaled JPY205.159 billion, or JPY241.04 per share. This ......

Tanabe Pharma America Remains Focused on Rare Disease Innovation and Addressing Unmet Patient Needs JERSEY CITY, N.J., April 1, 2026 /PRNewswire/ -- Tanabe Pharma America, Inc. (TPA), the wholly owned subsidiary of Tanabe Pharma Corporation, today announced the finalization of the......

 Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong Commercial Platform in Rare Disease to Support Future LaunchesOSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer of all rights for RADICAVA (edaravone), including intellectual property rights and sales rights, in major countries and regions to our company from Tanabe Pharma Corporation. Transfer of rights in additional countries and regions is forthcoming. The acquisition and integration of RADICAVA team members, programs and platforms adds to ongoing strategic investments in rare disease and establishes Shionogi as a commercially viable rare disease company ready to introduce new treatments to patients with unmet medical needs. RADICAVA is approved by the U.S...

GSK PLC and Shionogi & Co Ltd on Wednesday said the replacement of Pfizer Inc's stake in the ViiV Healthcare Ltd joint...

NEW YORK CITY (dpa-AFX) - GSK plc (GSK, GSK.L), and Shionogi & Co. announced the completion of the transaction for the 11.7% economic interest in ViiV Healthcare previously held by Pfizer (PFE) to......

Das Instrument SH0 JP3347200002 SHIONOGI + CO. LTD EQUITY wird ex Dividende/Zinsen gehandelt am 30.03.2026 The instrument SH0 JP3347200002 SHIONOGI + CO. LTD EQUITY has its ex-dividend/interest day on 30.03.2026...

The invasive fungal infections market is expected to grow by 2034, owing to the approval of new agents such as Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica), Olorofim (F901318) (Shionogi/F2G), Opelconazole (PC945) (Pulmocide), and others in frontline and......

WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum (“molluscum”)....

Shionogi & Co. (SGIOY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) reported earnings for its nine months that Increased, from last yearThe company's bottom line came in at JPY158.225 billion, or JPY185.91 per share. ......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Osaka, Jan. 20 (Jiji Press)--Japanese pharmaceutical company Shionogi & Co. said Tuesday that it will spend 2,125 million dollars to raise its stake in British HIV drugs company ViiV Healthcare Ltd. from 10 pct to 21.7 pct. ViiV will issue new shares to Shionogi for the additional investment. Procedures are expected to be completed by the end of March. ViiV will cancel the 11.7 pct stake ......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...